Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D5W7BG
|
|||
| Drug Name |
M012
|
|||
| Synonyms |
Benzal chloride; 98-87-3; (DICHLOROMETHYL)BENZENE; alpha,alpha-Dichlorotoluene; Benzylidene chloride; Benzene, (dichloromethyl)-; Benzyl dichloride; Dichloromethylbenzene; Benzylene chloride; Chlorobenzal; Dichlorophenylmethane; DICHLOROTOLUENE; Chlorure de benzylidene; Benzene, dichloromethyl-; RCRA waste number U017; NSC 7915; Benzylidene dichloride; UNII-222447TR16; 29797-40-8; alpha,alpha-Dichlorotoluene; CHEBI:82273; Toluene, .alpha.,.alpha.-dichloro-; 222447TR16; DSSTox_CID_5014; DSSTox_RID_77628; DSSTox_GSID_25014; CAS-98-87-3; CCRIS 959; Toluene, alpha,alpha-dichloro-; Cloruro de bencilideno; Chlorure de benzylidene [French]; Cloruro de bencilideno [Spanish]; HSDB 5322; EINECS 202-709-2; UN1886; RCRA waste no. U017; benzalchlorid; BRN 1099407; AI3-28597; chlorobenzyl chloride; EINECS 249-854-8; Benzal chloride???; WLN: GYGR; 1-(dichloromethyl)benzene; alpha-alpha-Dichlorotoluene; EC 202-709-2; EC 249-854-8; SCHEMBL28353; 4-05-00-00817 (Beilstein Handbook Reference); alpha,alpha-Dichlortoluene; CHEMBL1412576; DTXSID6025014; Cl[C](Cl)C1=CC=CC=C1; NSC7915; alpha,alpha-Dichlorotoluene, 95%; ALPHA,ALPHA-DICHLORO-TOLUENE; NSC-7915; ZINC1586312; Tox21_201313; Tox21_300171; MFCD00000829; AKOS015902605; FS-4304; MCULE-5551252494; Toluene, alpha,alpha-dichloro- (8CI); UN 1886; NCGC00091362-01; NCGC00091362-02; NCGC00091362-03; NCGC00254144-01; NCGC00258865-01; Benzylidene chloride [UN1886] [Poison]; FT-0694812; C19165; Q419420; alpha,alpha-Dichlorotoluene, PESTANAL(R), analytical standard
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 1 | [1] | |
| Polycythemia vera [ICD-11: 2A20.4; ICD-10: D45] | Phase 1 | [1] | ||
| Thalassemia [ICD-11: 3A50] | Phase 1 | [1] | ||
| Company |
Merganser Biotech
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C7H6Cl2
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)C(Cl)Cl
|
|||
| InChI |
1S/C7H6Cl2/c8-7(9)6-4-2-1-3-5-6/h1-5,7H
|
|||
| InChIKey |
CAHQGWAXKLQREW-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 98-87-3
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:82273
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Solute carrier family 40 member 1 (SLC40A1) | Target Info | Agonist | [2] |
| KEGG Pathway | Mineral absorption | |||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Reactome | Iron uptake and transport | |||
| WikiPathways | Iron uptake and transport | |||
| Iron metabolism in placenta | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov. 2017 Jun;16(6):400-423. | |||
| REF 2 | Hepcidin agonists as therapeutic tools. Blood. 2018 Apr 19;131(16):1790-1794. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.